Benzinga.com9h
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
BofA Securities cuts Moderna's price target from $110 to $90 due to vaccine sales concerns. Moderna faces tough ...
Reuters on MSN1d
Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...
MarketWatch5h
Moderna Inc. stock underperforms Friday when compared to competitors
Shares of Moderna Inc. MRNA shed 6.86% to $46.83 Friday, on what proved to be an all-around favorable trading session for ...
Moderna sales get lift from early nod for newest COVID shot
Moderna delivered better-than-expected profit and sales in the third quarter after an early start to sales of this season’s ...
Moderna Stock Gains on Better-Than-Expected Covid-19 Vaccine Sales
Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...
Moderna’s stock pops after biotech ekes out a surprise profit, and revenue beats by a wide margin
Moderna Inc.’s stock jumped 5% early Thursday, after the company’s third-quarter earnings showed an unexpected profit and ...
Moderna price target lowered to $111 from $125 at Barclays
Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...
BioPharma Dive1d
Moderna earnings beat forecasts, but analysts question whether sales spike will last
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
Moderna EPS Beats Estimates, Sales Rise
Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...
Moderna’s Bancel steps down as sales chief, keeps CEO role
Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter.
Business Insider18h
Oppenheimer Sticks to Its Hold Rating for Moderna (MRNA)
In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on Moderna (MRNA – Research Report). The company’s shares closed yesterday at $50.28. Olson covers the Healthcare ...